> 2 Ndrepepa G，Braun S，von Beckerath N,et al.Oxidized low density lipoproteins，statin therapy and severity of coronary artery disease〔J〕.Clin Chim Acta，2005;360(12):17886.
3 Halcox JP，Deanfield JE.Beyond the laboratory：clinical implications for statin pleiotropy〔J〕.Circulation，2004;109(21 Suppl 1):Ⅱ428.
4 Ito MK，Talbert RL，Tsimikas S.Statinassociated pleiotropy：possible beneficial effects beyond cholesterol reduction〔J〕.Pharmacotherapy ，2006;26(7 Pt 2):85S97S.
5 Liao JK.Clinical implications for statin pleiotropy〔J〕.Curr Opin Lipidol，2005;16(6):6249.
6 Rubin LJ.Therapy of pulmonary hypertension：the evolution from vasodilators to antiproliferative agents〔J〕.Am J Respir Crit Care Med，2002;166(10):13089.
7 Nishimura T，Faul JL，Berry GJ,et al.Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats〔J〕.Am J Respir Crit Care Med，2002;166(10):14038.
8 Voelkel NF，Cool C，TaracevieneStewart L,et al.Janus face of vascular endothelial growth factor：the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension〔J〕.Crit Care Med，2002;30(5 Suppl):S2516.
9 Kohno M，Shinomiya K，Abe S,et al.Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMGCoA reductase inhibitor，pitavastatin〔J〕.Hypertens Res，2002;25(2):27985.
10 Kalinowski L，Dobrucki IT，Malinski T.Cerivastatin potentiates nitric oxide release and eNOS expression through inhibition of isoprenoids synthesis〔J〕.J Physiol Pharmacol，2002;53(4 Pt 1):58595.
11 Murata T，Sato K，Hori M,et al.Decreased endothelial nitricoxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxiainduced pulmonary hypertension〔J〕.J Biol Chem，2002;277(46):4408592.
12 Girgis RE，Li D，Zhan X,et al.Attenuation of chronic hypoxic pulmonary hypertension by sim
上一页 [1] [2] [3] [4] 下一页
您现在的位置： 绿色健康网 >> 医学论文 >> 内科论文 >> 正文